|Poll|May 20, 2019

Mini Quiz: Schizophrenia Research

Current trials are investigating adjunctive monoclonal antibody immunotherapy in schizophrenia. Take the quiz and learn more.

Current trials are investigating adjunctive monoclonal antibody immunotherapy in schizophrenia with all of the following agents EXCEPT:

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Exploitation of Individuals With Psychosis

BySamya Isa, MD,Nidal Moukaddam, MD, PhD,Katharine Wojcik, PhD

August 25th 2026

Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia

ByNicole C. Sears, NP,Michael M. Halassa, MD, PhD

August 13th 2026

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

ByPragyan Sharma, MD, MSc,Samara White, PharmD,Ranel Troy Santos, PharmD, BCPP

August 5th 2026

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

ByGustavo Alva, MD, DFAPA

July 31st 2026

Real-World and Long-Term Trial Data Show Xanomeline/Trospium Cuts Hospitalizations, Antipsychotic Burden in Schizophrenia

ByPsychiatric Times Editors

July 30th 2026

Latest CME

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Mini Quiz: Schizophrenia Research

Related Content

Exploitation of Individuals With Psychosis

Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

Real-World and Long-Term Trial Data Show Xanomeline/Trospium Cuts Hospitalizations, Antipsychotic Burden in Schizophrenia

Latest CME

Jersey City Psychiatry

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Trending on Psychiatric Times

DT120 (Lysergide) ODT Receives Breakthrough Therapy Designation for Treatment of MDD

Anita Clayton, MD, on Diagnosing and Discussing Sexual Dysfunction

Morning Rounds: September 1-8

Agitation Associated with Dementia Due to Alzheimer’s Disease: How Common Is It, and How Does It Present?

Podcast: Tips for Treating Sexual Dysfunction With Anita H. Clayton, MD